11:29 AM EST - Fennec Pharmaceuticals Inc : Announced that the U.S. Food and Drug Administration has granted Orphan Drug Exclusivity to PEDMARK® (sodium thiosulfate injection), which is indicated to reduce the risk of ototoxicity, or hearing loss, associated with cisplatin use in pediatric patients one month of age and older with localized, non-metastatic solid tumors. Fennec Pharmaceuticals Inc
shares T.FRX are trading up $0.53 at $13.07.
